



Encorafenib

Catalog No: tcsc2289

Available Sizes
Size: 1mg
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Specifications
CAS No: 1269440-17-6
Formula: C ₂₂ H ₂₇ CIFN ₇ O ₄ S
Pathway: MAPK/ERK Pathway
Target: Raf
Purity / Grade: >98%
Solubility: DMSO : 50 mg/mL (92.59 mM; Need ultrasonic)
Alternative Names: LGX818





Observed Molecular Weight:

540.01

Product Description

Encorafenib (LGX818) is a highly potent **RAF** inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E (**EC**₅₀=4 nM).

IC50 & Target: IC50: 0.3 nM (BRaf^{V600E})

In Vitro: Encorafenib (LGX818) is a potent drug that can prevents diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf^[1]. Encorafenib (LGX818) (10 nM) suppresses the ERK/MAPK pathway and displays marked inhibition of pERK in A375, G361 and SK-MEL-24 cells. 10 nM Encorafenib (LGX818) treatment for 12 days potently inhibits colony formation in A375, G361 and SK-MEL-24 cells, but not in RPMI7951 and C8161 cells. Encorafenib (LGX818) treatment induces a steady increase in the β -catenin level in G361 cells over time^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!